Cargando…
EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP
BACKGROUND: Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is used as standard frontline regimen for diffuse large B-cell lymphoma (DLBCL). The landscape of somatic mutations in DLBCL revealed that inactivation of EP300 plays an important role in lymphomagen...
Autores principales: | Li, Jiao, Ding, Ning, Wang, Xiaogan, Mi, Lan, Ping, Lingyan, Jin, Xuan, Liu, Yalu, Ying, Zhitao, Xie, Yan, Liu, Weiping, Song, Yuqin, Zhu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513029/ https://www.ncbi.nlm.nih.gov/pubmed/28725161 http://dx.doi.org/10.1186/s12935-017-0439-1 |
Ejemplares similares
-
TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017) -
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014) -
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma
por: Liu, Yalu, et al.
Publicado: (2019) -
Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma
por: Ding, Huirong, et al.
Publicado: (2013) -
LINC01605, regulated by the EP300-SMYD2 complex, potentiates the binding between METTL3 and SPTBN2 in colorectal cancer
por: Yue, Meng, et al.
Publicado: (2021)